Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
68 hedge funds and large institutions have $224M invested in Syros Pharmaceuticals, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 25 increasing their positions, 9 reducing their positions, and 5 closing their positions.
380% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 5
178% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 9
39% more funds holding
Funds holding: 49 → 68 (+19)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
11% less capital invested
Capital invested by funds: $251M → $224M (-$26.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.15M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$2.26M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$2.2M |
| 5 |
Millennium Management
New York
|
+$2.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$30.1M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$6.24M |
| 3 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$386K |
| 4 |
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
|
-$156K |
| 5 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$148K |
SYRS Hedge Fund Activity: Q3 2017 in Review
68 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q3 2017, worth a combined $224M — down 11% from $251M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new SYRS positions and 5 closed out — a net gain of 19 holders — while 25 added to existing stakes and 9 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $5.8M. The largest seller was Flagship Pioneering, cutting an estimated $30.1M.
- 68 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q3 2017, up from 49 in Q2 2017.
- Funds reported $224M of Syros Pharmaceuticals, Inc. Common Stock stock for Q3 2017, down 11% quarter-over-quarter.
- 24 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q3 2017 and 5 closed out, a net change of +19 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q3 2017 was T. Rowe Price Associates, an estimated $5.8M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q3 2017 was Flagship Pioneering, an estimated $30.1M sold.
Based on aggregated 13F filings for Q3 2017.